A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 70
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : YLS
Long Form : year of life saved
No. Year Title Co-occurring Abbreviation
2020 A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease. CEPAC, HIV, HOPE, ICC, ICER, individual benefit, MSM, PrEP, PWID
2020 Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa. CT, HT, IC, ICER, QC, R e
2020 Strengthening Existing Laboratory-Based Systems vs. Investing in Point-of-Care Assays for Early Infant Diagnosis of HIV: A Model-Based Cost-Effectiveness Analysis. ART, EID, ICERs, LAB, LE, POC, POC, S-LAB
2020 The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. HIV, ICER, MSM, MSM, PrEP, PWID
2020 The cost-effectiveness of human papillomavirus self-collection among cervical cancer screening non-attenders in El Salvador. HPV
2019 Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis. VIA
2019 Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Cote d'Ivoire: A model-based analysis. ICERs, PWH
2019 Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients with HIV in Africa: a microsimulation modelling study. ICER
2019 Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector. DMCs, ICERs, TB, Truenat DMC
10  2018 Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial. ASPIRE, HPV, ICERs, VIA
11  2018 Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study. ART, DAA, HCV, ICERs, NSP, OST, PWID
12  2018 The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India. ART, CEPAC, DTG, EFV, ICERs, SOC, TDF
13  2018 The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil. CEPAC, GDP, ICER, MSM, PrEP, SOC, TGW, USD
14  2018 The Optimal Age for Screening Adolescents and Young Adults Without Identified Risk Factors for HIV. AYA
15  2018 Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness. HIV, ICER, PY, UNAIDS, VCT
16  2017 Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. ICER, MRI, RRM
17  2017 Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting. ICERs
18  2017 Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua. HPV, ICER, Pap, VIA
19  2017 Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon. CC, GDP
20  2017 Societal costs and effects of implementing population-based mammography screening in Greenland. QALY
21  2017 The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations. CLIN, LAB-CD4, POC-CD4
22  2017 To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. ---
23  2015 Improving NCCN guideline-adherent care for ovarian cancer: Value of an intervention. ICERs, NCCN, SQ
24  2014 Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cote d'Ivoire. ART, ICERs
25  2014 Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. CEPAC-I, GDP, ICER
26  2014 The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysis. ART, ICERs, LAB-CD4, POC-CD4
27  2013 Clinical impact and cost-effectiveness of expanded voluntary HIV testing in India. ART, ICERs, PY
28  2013 Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. HIV, LE, sdNVP, WHO
29  2013 Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. DALYs, HPV
30  2013 The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. ART, HIV, WT
31  2012 Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country. HAART
32  2012 Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. HPV, VIA
33  2012 Earlier initialization of highly active antiretroviral therapy is associated with long-term survival and is cost-effective: findings from a deterministic model of a 10-year Ugandan cohort. ICER
34  2012 Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. ART, CEPAC
35  2012 Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in Eastern Africa. ---
36  2012 Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. GDP, HPV
37  2012 The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. ART, ICERs, TB
38  2012 The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. ICER, IPT, TB
39  2011 Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. ART
40  2011 Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. ASCUS, HPV
41  2010 Alternative strategies to reduce maternal mortality in India: a cost-effectiveness analysis. EmOC, GDP
42  2010 Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. HC2, HPV
43  2010 Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. TB
44  2010 Cost-effectiveness of human papillomavirus vaccination and screening in Spain. HPV
45  2010 Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. ART, WHO
46  2009 Cost effectiveness of a test to detect metastases for endometrial cancer. ICER, SEER
47  2009 Cost-effectiveness analysis of annual screening strategies for endometrial cancer. BMI, ICER
48  2009 Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. ---
49  2008 Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? ---
50  2007 Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. HCV, HIV
51  2007 Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis. CR, HDR, LDR, PET/CT
52  2007 The cost-effectiveness of antiretroviral therapy for treating HIV disease in the Caribbean. ART, OECS
53  2007 The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. HPV
54  2006 Cost-effectiveness analysis of antifungal treatment for patients on chemotherapy. ---
55  2004 Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. ---
56  2003 An economic viewpoint on alternative strategies for identifying persons with hereditary nonpolyposis colorectal cancer. HNPCC
57  2003 [Current framework of biotechnology products according to the available pharmacoeconomic studies]. ---
58  2002 Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. ASCUS, HPV, QALYs
59  2001 Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. DVI, HPV
60  2000 A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care. ---
61  1999 Screening for malignant melanoma: A cost-effectiveness analysis. ---
62  1999 Selective preoperative cardiac screening improves five-year survival in patients undergoing major vascular surgery: a cost-effectiveness analysis. ---
63  1999 Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review. NSCLC
64  1998 Cost effectiveness of coronary heart disease prevention strategies in adults. CHD, QALY
65  1997 The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients. ---
66  1996 Enoxaparin. A pharmacoeconomic appraisal of its use in thromboembolic prophylaxis after total hip arthroplasty. DVT, LMWH, PE, THA, UFH
67  1996 Validating literature-based models with direct clinical trial results: the cost-effectiveness of secondary prophylaxis for PCP in AIDS patients. PCP
68  1995 Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction. PTCA
69  1995 Evaluating and improving the cost-effectiveness of the implantable cardioverter-defibrillator. EP, ICD
70  1993 Cost-effectiveness of a tobacco 'quit and win' contest in Sweden. ---